Rafael Torre

Clinical Psychopharmacologist

Data updated

Papers

8 publications

Trials

0 clinical trials

Links

Research Footprint

Rafael Torre appears in 8 tracked papers (2006–2023), most studied alongside MDMA, 2C-X and Ayahuasca, across Healthy Volunteers, Depressive Disorders and Medicinal Chemistry & Drug Development.

Most-cited paper: Pharmacology of MDMA in humans (178 citations).

Frequent co-authors: Rafael De La Torre, Magí Farré and Johannes Ramaekers.

Background & Research

Rafael de la Torre is a clinical psychopharmacologist whose work focuses on the human pharmacology and subjective effects of entactogens and substituted stimulants. His publications and trial involvement include observational and experimental studies of 2C‑B, comparative human pharmacology of mephedrone versus MDMA, and mechanistic investigations of MDMA’s acute psychological effects. He has contributed to bridging controlled human psychopharmacology with psychometric, genetic and receptor‑mechanism approaches.

De la Torre’s research has addressed both population‑level effects (for example, mood changes in polydrug ecstasy users) and receptor and genotype moderators of drug response — notably studies implicating the 5‑HT2A receptor in specific MDMA‑induced changes in emotional processing, and work examining how serotonin transporter genotype (l‑allele homozygosity) relates to MDMA’s effects on depressive mood ratings in female users. Methodologically, his contributions span observational human studies, controlled pharmacological challenge designs, psychometric assessment and incorporation of genetic and receptor‑blockade probes to parse mechanisms underlying subjective and affective drug effects.

Affiliations

Institutions, companies, and organisations Rafael Torre is associated with.